FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

Patients taking the Rasonque pill achieved median survival of 13.2 months, nearly double the chemo group...

Redirecting to full article...